Department of Vascular Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Department of Vascular Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
PeerJ. 2024 Oct 10;12:e18189. doi: 10.7717/peerj.18189. eCollection 2024.
To investigate the mid-term efficacy and patency rate of TurboHawk peripheral plaque excision system in the treatment of femoral popliteal artery lesions with different Global Limb Anatomic Staging System (GLASS) grades.
The clinical data of 141 patients with femoral popliteal arteriosclerosis obliterans who were treated with TurboHawk from January 2018 to July 2022 in our institution were retrospectively analyzed. There were 109 male patients and 32 female patients. Recordings were made of the patient's symptoms of limb ischemia, technical success rate, primary patency rate of target vessels, ankle brachial index (ABI), GLASS grades, postoperative complications, and a statistical analysis with the patient's preoperative treatment was conducted.
All patients had improved limb ischemia symptoms to varying degrees after surgery, with a technical success rate of 100% (femoral artery puncture and superficial femoral artery recanalization) without bleeding, hematoma, pseudoaneurysm, arteriovenous fistula or other complications. The follow-up period was 1-24 months, during which the severity of claudication, resting pain, and toe ulcers significantly improved. The primary patency rate of the target vessel was 98.58% (139/141), and the ABI significantly increased on the second day, three months, and six months after surgery compared to before surgery. No major adverse events were found during follow-up. The patency rates at 1, 6, 12 and 24 months after intervention were 100%, 80%, 75% and 60% respectively.
The mid-term efficacy and patency rate of TurboHawk in the treatment of femoral popliteal artery lesions with GLASS I patients have the best mid-term prognosis, the highest mid-term survival rate, and the highest vascular patency. The plaque removal system has proven to be an effective treatment for individual localized chronic total occlusion lesions. Additionally, the TurboHawk system provides a safe and minimally invasive treatment alternative for superficial femoral artery conditions, achieving significant therapeutic results within a brief period.
探讨 TurboHawk 外周斑块切除系统治疗不同 Global Limb Anatomic Staging System（GLASS）分级股腘动脉病变的中期疗效及通畅率。
回顾性分析 2018 年 1 月至 2022 年 7 月我院采用 TurboHawk 治疗的 141 例股腘动脉硬化闭塞症患者的临床资料，其中男 109 例，女 32 例。记录患者肢体缺血症状、技术成功率、靶血管的初始通畅率、踝肱指数（ABI）、GLASS 分级、术后并发症等，并与患者术前治疗进行统计学分析。
所有患者术后肢体缺血症状均不同程度改善，技术成功率 100%（股动脉穿刺、股浅动脉再通），无出血、血肿、假性动脉瘤、动静脉瘘等并发症。随访 1~24 个月，跛行、静息痛、足趾溃疡程度均明显改善。靶血管的初始通畅率为 98.58%（139/141），术后第 2 天、3 个月、6 个月的 ABI 均明显高于术前。随访期间无重大不良事件发生。介入治疗后 1、6、12 和 24 个月的通畅率分别为 100%、80%、75%和 60%。
TurboHawk 治疗 GLASSⅠ级患者股腘动脉病变的中期疗效及通畅率最好，中期生存率最高，血管通畅率最高。斑块切除系统已被证明是治疗个别局限性慢性完全闭塞病变的有效方法。此外，TurboHawk 系统为股浅动脉病变提供了一种安全、微创的治疗选择，可在短时间内获得显著的治疗效果。
